NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: NeuroOne's Nasdaq Compliance Extension and Stock Listing Status
TL;DR
NeuroOne gained a 180-day extension to boost its stock price above $1, providing investors a window to capitalize on potential recovery before possible delisting.
NeuroOne received a 180-day extension until May 2026 to meet Nasdaq's minimum $1 bid price requirement, maintaining current listing status while working to regain compliance.
This extension allows NeuroOne to continue developing neurological disorder treatments that could improve patient outcomes and reduce healthcare costs for those in need.
NeuroOne develops innovative EEG and brain stimulation technologies for epilepsy and Parkinson's patients while navigating stock market compliance requirements.
Found this article helpful?
Share it with your network and spread the knowledge!
NeuroOne Medical Technologies has received a 180-day extension from Nasdaq until May 4, 2026, to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market.
The company was not in compliance with Nasdaq's minimum bid price requirement for 30 consecutive business days and had not regained compliance by the original November 3, 2025 deadline, requiring an extension to avoid potential delisting.
The extension has no immediate effect on the continued listing status of the company's common stock on the Nasdaq Capital Market, which remains fully effective during the extension period.
If the company does not regain compliance by May 4, 2026, Nasdaq will notify NeuroOne that its stock will be subject to delisting, at which point the company may appeal to a Nasdaq Hearing Panel.
The company will continue to monitor its closing bid price and has advised Nasdaq of its intent to cure the deficiency within the 180-day extension period.
NeuroOne is a medical technology company focused on developing and commercializing minimally invasive solutions for EEG recording, monitoring, ablation, drug delivery and stimulation for patients with neurological disorders such as epilepsy, Parkinson's disease, and chronic pain.
For more information about NeuroOne Medical Technologies Corporation, visit their website at nmtc1.com.
Maintaining Nasdaq compliance is crucial for the company's continued access to public markets, investor confidence, and the ability to trade on a major stock exchange, which affects liquidity and corporate credibility.
Curated from NewMediaWire
